Pharming Begin Period Cash Flow from 2010 to 2025

PHAR Stock  USD 8.68  0.14  1.64%   
Pharming Group Begin Period Cash Flow yearly trend continues to be relatively stable with very little volatility. Begin Period Cash Flow is likely to grow to about 250.4 M this year. Begin Period Cash Flow is the amount of cash Pharming Group NV has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
2009-03-31
Previous Quarter
51.9 M
Current Value
47.1 M
Quarterly Volatility
64.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 19.2 M, Interest Expense of 6.4 M or Selling And Marketing Expenses of 7.4 M, as well as many indicators such as Price To Sales Ratio of 4.16, Dividend Yield of 0.0 or PTB Ratio of 3.92. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
  
Check out the analysis of Pharming Group Correlation against competitors.

Latest Pharming Group's Begin Period Cash Flow Growth Pattern

Below is the plot of the Begin Period Cash Flow of Pharming Group NV over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Pharming Group's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharming Group's overall financial position and show how it may be relating to other accounts over time.
Begin Period Cash Flow10 Years Trend
Slightly volatile
   Begin Period Cash Flow   
       Timeline  

Pharming Begin Period Cash Flow Regression Statistics

Arithmetic Mean94,152,238
Geometric Mean54,053,490
Coefficient Of Variation94.42
Mean Deviation75,808,929
Median68,626,172
Standard Deviation88,897,390
Sample Variance7902.7T
Range243.7M
R-Value0.92
Mean Square Error1238.2T
R-Squared0.85
Slope17,252,996
Total Sum of Squares118541.2T

Pharming Begin Period Cash Flow History

2025250.4 M
2024238.4 M
2023207.3 M
2022191.9 M
2021189.2 M
202081.5 M
201991.3 M

About Pharming Group Financial Statements

Pharming Group shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. The changes in Pharming Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharming Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Begin Period Cash Flow238.4 M250.4 M

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.